Help support Women / Men with Metastatic Breast Cancer by signing our petition

0 have signed. Let’s get to 5,000!

As of today, women newly diagnosed with metastatic breast cancer (‘Newly diagnosed’ means you have either not received any treatment for metastatic breast cancer or you may have received up to 28 days of treatment with letrozole or anastrozole) will be able to access the CDK 4/6 inhibitor drug ribociclib (kisqali) & Palbociclib (Ibrance) through the PBS for $39.50 a month ($6.40 for concession card holders) rather than $5,000 a month.

Ribociclib (Kisqali®) & Palbociclib (Ibrance) belongs to a new class of drugs called CDK inhibitors. They are used to treat people living with a particular type of metastatic (advanced) breast cancer, and have been shown in clinical trials to extend the length of time before the cancer spreads by up to 26 months. They are taken as tablets and do not cause common cancer treatment side effects such as hair loss and nausea, so people using them have a good quality of life.

This is GREAT NEWS!!! As this will give women/men more hope in fighting breast cancer.


Why is the price only slashed for newly diagnosed women/men ??? what about women/men who have been battling cancer for years, why would they still need to pay $5000 per month if they want this treatment – well out of the reach for most Australian families, including mine. ??

We believe It should be equal across the board & to give hope to everyone fighting this disease !!

Please help us tell Hon Greg Hunt MP, the Minister of Health, that we matter also and should all have a chance to extend our lives. We are asking him to work with the Pharmaceutical Novartis and Pfizer to show compassion & work together to find a solution to ensure the drugs becomes available through the PBS so all Australian women/men can access the drug on the PBS as soon as possible.

Thank you for signing and sharing this petition.

Maria Camuglia
Daughter of a Metastatic Breast Cancer Patient